VIDEO: Reduced-dose irradiation, chemotherapy for medulloblastoma lowers long-term effects

ByMichael J. Fisher, MD

ByGeorgia I Salvaryn

Fact checked byMindy Valcarcel, MS

PHILADELPHIA — In this video, Michael Fisher, MD, discusses the results of the SJMB12 (NCT01878617) trial.

The study, presented at the International Symposium on Pediatric Neuro-Oncology, found that reduced-dose craniospinal irradiation (CSI) and reduced-dose cyclophosphamide-based chemotherapy maintained a high PFS when treating patients with low-risk wingless-related integration site medulloblastoma (WNT-MB).

“It appears that when you [use reduced-dose CSI and reduced-dose cyclophosphamide-based chemotherapy], at least to-date, [researchers] are not seeing any of some of the long-term toxicities one might see [when treating these patients],” Fisher, a professor of pediatrics at University of Pennsylvania’s Perelman School of Medicine, said.

Reference:

Robinson GW, et al. Abstract MDB-92. Presented at: ISPNO; June 28-July 2, 2024.

Published by:

Sources/Disclosures

Collapse

Disclosures: Fisher reports no relevant financial disclosures.

Take Homes from ISPNO

Read more

VIDEO: Reduced-dose irradiation, chemotherapy for medulloblastoma lowers long-term effects

Reference:

Related Content